PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Epilepsy (Phenobarbital - Epilepsy)

Records returned : 40 (on 24 Nov 2024 at 14:14:36). .

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
04.08.01
04.08.02
Phenobarbital
Epilepsy
Blue
Formulations :
  • Elixir
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Important
Ensure that the patient is maintained on a specific manufacturer’s product
04.08.01
04.08.02
Epilepsy
Blue
Formulations :
  • Liquid
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Un
Important
Ensure that the patient is maintained on a specific manufacturer’s product
Unlicensed phenobarbital liquid 50mg/5ml (sugar and alcohol free) for paediatric use (as recommended by the RCPCH and NPPG).
04.08.01
04.09.03
Primidone
Epilepsy
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Prescribe by brand - ensure patient is maintained on a specific product.
04.07.04
04.08.01
Topiramate
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Plan required for females of childbearing potential.
Capsules (Sprinkle) reserved for use in patients who cannot swallow tablets. Liquid reserved for patients who cannot swallow tablets or capsules
04.08.01
Vigabatrin
Epilepsy
Blue
Formulations :
  • Sachets (powder)
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Specialist initiation before transfer of prescribing to primary care
04.08.01
04.08.02
Phenytoin
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Ensure that the patient is maintained on a specific manufacturer’s product. Phenytoin sodium is NOT EQUIVALENT to Phenytoin base (suspension). When switching between products, 100mg of phenytoin sodium is approximately equivalent to 92mg of phenytoin base.
04.07.03
04.07.04
04.08.01
Pregabalin
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Important
Capsules are more cost effective than tablets
04.08.01
Sodium valproate (NON childbearing potential)
Epilepsy
Blue
Formulations :
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
  • Crushable tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Epilepsy
Blue
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Zonisamide
Epilepsy
Blue
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Epilepsy
Blue
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Zonisamide 20mg/ml is the only licensed oral suspension available.
04.07.03
04.08.01
Carbamazepine
Epilepsy
Blue
Formulations :
  • Modified release tablets
  • Oral suspension
  • Suppositories
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Ensure that the patient is maintained on a specific manufacturer’s product
04.08.01
Brivaracetam
Epilepsy
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics. Only for use when levetiracetam has not been effective or tolerated.
04.08.01
Clobazam
Epilepsy
Blue
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
04.08.01
04.08.02
Clonazepam
Epilepsy
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
04.08.01
Ethosuximide
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
For absence, atypical and myoclonic seizures
04.07.03
04.07.04
04.08.01
Gabapentin
Epilepsy
Blue
Formulations :
  • Capsules
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
04.08.01
Lacosamide
Epilepsy
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Lamotrigine
Epilepsy
Blue
Formulations :
  • Dispersible tablets
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Levetiracetam
Epilepsy
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Epilepsy
Blue
Formulations :
  • Granules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Oxcarbazepine
Epilepsy
Blue
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Perampanel
Epilepsy
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Requires specialist initiation and supply for at least 12 weeks prior to a transfer of care to primary care prescribers
04.08.01
Eslicarbazepine acetate
Epilepsy
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
Only when 1st-line and 1st-line adjunctive agents have been unsuccessful
04.08.01
Rufinamide
Epilepsy
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
SASH - restricted to paediatrics only. RSCH - only initiate on recommendation from a tertiary referral centre.
04.08.01
Epilepsy
Amber
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
Important
RSCH - only initiate on recommendation from a tertiary referral centre.
04.08.01
Sodium valproate (with childbearing potential)
Epilepsy
Amber
Formulations :
  • Gastro-resistant tablets
  • Modified release tablets
  • Oral solution
  • Tablets
  • Crushable tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Epilepsy
Amber
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Stiripentol
Epilepsy
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Initiation and adjustment by consultant paediatricians only.
04.08.01
Sodium valproate (with childbearing potential)
Epilepsy
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy Prevention Programme required. See MHRA advice
04.08.01
Sodium valproate (NON childbearing potential)
Epilepsy
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Piracetam
Epilepsy
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
10.02.02
Cannabis (medicinal)
Epilepsy
Red
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Important
Specialist centres only (including ongoing supply)
04.08.01
Cenobamate
Epilepsy
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
For initiation by tertiary centres only
04.08.01
Levetiracetam
Epilepsy
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Lacosamide
Epilepsy
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.08.01
Felbamate
Epilepsy
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
04.08.01
Brivaracetam
Epilepsy
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics. Only for use when levetiracetam has not been effective or tolerated.
04.08.01
Vigabatrin
Epilepsy
Non Formulary
Formulations :
  • Soluble tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
04.08.01
Tiagabine
Epilepsy
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More